7
|
Kempen HJ, Asztalos BF, Moerland M, Jeyarajah E, Otvos J, Kallend DG, Bellibas SE, Wijngaard PLJ. High-Density Lipoprotein Subfractions and Cholesterol Efflux Capacities After Infusion of MDCO-216 (Apolipoprotein A-IMilano/Palmitoyl-Oleoyl-Phosphatidylcholine) in Healthy Volunteers and Stable Coronary Artery Disease Patients. Arterioscler Thromb Vasc Biol 2016; 36:736-42. [PMID: 26916733 DOI: 10.1161/atvbaha.115.307052] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Accepted: 02/12/2016] [Indexed: 11/16/2022]
Abstract
OBJECTIVE To determine effects of single ascending doses of MDCO-216 on high-density lipoprotein (HDL) subfractions in relation to changes in cholesterol efflux capacity in healthy volunteers and in patients with stable angina pectoris. APPROACH AND RESULTS Doses of 5- (in volunteers only), 10-, 20-, 30-, and 40-mg/kg MDCO-216 were infused during 2 hours, and plasma and serum were collected during 30 days. Plasma levels of HDL subfractions were assessed by 2-dimensional gel electrophoresis, immunoblotting, and image analysis. Lipoprotein particle concentrations and sizes were also assessed by proton nuclear magnetic resonance ((1)H-NMR). There was a rapid dose-dependent increase of total apolipoprotein A-I (apoA-I) in pre-β1, α-1, and α-2 HDL levels and decrease in α-3 and α-4 HDL. Using a selective antibody apoA-IMilano was detected in the large α-1 and α-2 HDL on all doses and at each time point. ApoA-IMilano was also detected at the α-4 position but only at high doses. (1)H-NMR analysis similarly showed a rapid and dose-dependent shift from small- to large-sized HDL particles. The increase of basal and ATP-binding cassette transporter A1-mediated efflux capacities reported previously correlated strongly and independently with the increase in pre-β1-HDL and α-1 HDL, but not with that in α-2 HDL. CONCLUSIONS On infusion, MDCO-216 rapidly eliminates small HDL and leads to formation of α-1 and α-2 HDL containing both wild-type apoA-I and apoA-IMilano. In this process, endogenous apoA-I is liberated appearing as pre-β1-HDL. In addition to pre-β1-HDL, the newly formed α-1 HDL particle containing apoA-I Milano may have a direct effect on cholesterol efflux capacity.
Collapse
Affiliation(s)
- Herman J Kempen
- From The Medicines Company (Schweiz) GmbH, Zürich, Switzerland (H.J.K., D.G.K., P.L.J.W.); Lipid Metabolism Laboratory, Tufts University, Boston, MA (B.F.A.); Center of Human Drug Research, Leiden, The Netherlands (M.M.); Liposcience, Laboratory Corporation of America Holdings, Raleigh, NC (E.J., J.O.); and The Medicines Company Inc, Parsippany, NJ (S.E.B.).
| | - Bela F Asztalos
- From The Medicines Company (Schweiz) GmbH, Zürich, Switzerland (H.J.K., D.G.K., P.L.J.W.); Lipid Metabolism Laboratory, Tufts University, Boston, MA (B.F.A.); Center of Human Drug Research, Leiden, The Netherlands (M.M.); Liposcience, Laboratory Corporation of America Holdings, Raleigh, NC (E.J., J.O.); and The Medicines Company Inc, Parsippany, NJ (S.E.B.)
| | - Matthijs Moerland
- From The Medicines Company (Schweiz) GmbH, Zürich, Switzerland (H.J.K., D.G.K., P.L.J.W.); Lipid Metabolism Laboratory, Tufts University, Boston, MA (B.F.A.); Center of Human Drug Research, Leiden, The Netherlands (M.M.); Liposcience, Laboratory Corporation of America Holdings, Raleigh, NC (E.J., J.O.); and The Medicines Company Inc, Parsippany, NJ (S.E.B.)
| | - Elias Jeyarajah
- From The Medicines Company (Schweiz) GmbH, Zürich, Switzerland (H.J.K., D.G.K., P.L.J.W.); Lipid Metabolism Laboratory, Tufts University, Boston, MA (B.F.A.); Center of Human Drug Research, Leiden, The Netherlands (M.M.); Liposcience, Laboratory Corporation of America Holdings, Raleigh, NC (E.J., J.O.); and The Medicines Company Inc, Parsippany, NJ (S.E.B.)
| | - James Otvos
- From The Medicines Company (Schweiz) GmbH, Zürich, Switzerland (H.J.K., D.G.K., P.L.J.W.); Lipid Metabolism Laboratory, Tufts University, Boston, MA (B.F.A.); Center of Human Drug Research, Leiden, The Netherlands (M.M.); Liposcience, Laboratory Corporation of America Holdings, Raleigh, NC (E.J., J.O.); and The Medicines Company Inc, Parsippany, NJ (S.E.B.)
| | - David G Kallend
- From The Medicines Company (Schweiz) GmbH, Zürich, Switzerland (H.J.K., D.G.K., P.L.J.W.); Lipid Metabolism Laboratory, Tufts University, Boston, MA (B.F.A.); Center of Human Drug Research, Leiden, The Netherlands (M.M.); Liposcience, Laboratory Corporation of America Holdings, Raleigh, NC (E.J., J.O.); and The Medicines Company Inc, Parsippany, NJ (S.E.B.)
| | - S Eralp Bellibas
- From The Medicines Company (Schweiz) GmbH, Zürich, Switzerland (H.J.K., D.G.K., P.L.J.W.); Lipid Metabolism Laboratory, Tufts University, Boston, MA (B.F.A.); Center of Human Drug Research, Leiden, The Netherlands (M.M.); Liposcience, Laboratory Corporation of America Holdings, Raleigh, NC (E.J., J.O.); and The Medicines Company Inc, Parsippany, NJ (S.E.B.)
| | - Peter L J Wijngaard
- From The Medicines Company (Schweiz) GmbH, Zürich, Switzerland (H.J.K., D.G.K., P.L.J.W.); Lipid Metabolism Laboratory, Tufts University, Boston, MA (B.F.A.); Center of Human Drug Research, Leiden, The Netherlands (M.M.); Liposcience, Laboratory Corporation of America Holdings, Raleigh, NC (E.J., J.O.); and The Medicines Company Inc, Parsippany, NJ (S.E.B.)
| |
Collapse
|
12
|
Bellanger N, Orsoni A, Julia Z, Fournier N, Frisdal E, Duchene E, Bruckert E, Carrie A, Bonnefont-Rousselot D, Pirault J, Saint-Charles F, Chapman MJ, Lesnik P, Le Goff W, Guerin M. Atheroprotective Reverse Cholesterol Transport Pathway Is Defective in Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol 2011; 31:1675-81. [DOI: 10.1161/atvbaha.111.227181] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Natacha Bellanger
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Alexina Orsoni
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Zélie Julia
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Natalie Fournier
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Eric Frisdal
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Emilie Duchene
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Eric Bruckert
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Alain Carrie
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Dominique Bonnefont-Rousselot
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - John Pirault
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Flora Saint-Charles
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - M. John Chapman
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Philippe Lesnik
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Wilfried Le Goff
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| | - Maryse Guerin
- From the Institut National de la Santé et de la Recherche Médicale, UMRS 939 (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.) and Departments of Endocrinology, AP-HP (E.D., E.B.) and Metabolic Biochemistry, AP-HP (D.B.-R.), Hôpital de la Pitié, Paris, France; Université Pierre et Marie Curie, Paris, France (N.B., A.O., Z.J., E.F., E.D., E.B., A.C., J.P., F.S.-C., M.J.C., P.L., W.L.G., M.G.); Institute of CardioMetabolism and Nutrition, Hôpital de la Pitié, Paris,
| |
Collapse
|